IN THE NEWS

Ritedose news
and updates.

Learn more about Ritedose and the community.
Press releases, news stories, partnerships, community events, and more.

Media Inquiries

Schedule your interview and learn more about the Ritedose Company.

Alex Keown

Introducing Ritedose— the Largest CDMO Specializing in Blow-Fill-Seal Technology in the US

This overview explores Ritedose, the largest U.S. pharmaceutical CDMO, and how its aseptic Blow-Fill-Seal technology supports large-scale branded and generic drug manufacturing.

Ritedose Blow-Fill-Seal Technology | Aerial view of Ritedose pharmaceutical manufacturing facilities in Columbia, South Carolina, showcasing the largest U.S. Blow-Fill-Seal CDMO.

16January2026

How Ritedose Supports a Stable and Reliable Medication Supply

Learn how Ritedose safeguards patients’ access to critical medications with responsive, high-quality pharmaceutical manufacturing.

Automated pharmaceutical warehouse with a yellow robotic arm stacking cardboard boxes, illustrating Ritedose’s focus on transparency, efficiency, and solutions for drug shortages.

23December2025

Ritedose’s 2025 Year-In-Review highlights a year of growth, innovation, and purpose-driven impact, advancing patient access through expanded generics, operational excellence, and community investment.

18November2025

A Season of Gratitude and Purpose: A Thanksgiving Message from Jody Chastain, CEO of Ritedose

Ritedose has been built on the generosity, mentorship, and support of countless individuals and organizations across South Carolina. And with that good fortune comes a responsibility to give back to our patients, our people, and our community.

29October2025

Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution

The Ritedose Corporation (Ritedose) announced that the U.S. Food and Drug Administration (FDA) approved its manufacturing and distribution of Tobramycin Inhalation Solution to treat patients six years and older with infections of Pseudomonas aeruginosa, a common bacterial infection among cystic…

24September2025

Leading CDMO Enhances cGMP Lab Infrastructure to Strengthen Position

Ritedose is investing $17M to expand its cGMP labs, adding a 10,000 sq. ft. analytical chemistry facility and a 6,000 sq. ft. microbiology expansion to boost drug development and CDMO capabilities.

male scientist mixing chemicals in lab with text overlay "$17M expansion"

16September2025

How Blow-Fill-Seal Technology Ensures Sterile Medication Delivery

Discover how Ritedose leads the industry in delivering safe, scalable, and contamination-free drug products through advanced BFS innovation.

18June2025

Ritedose Unveils State-of-the-Art Distribution and Logistics Facility at Ritedose Performance Park

COLUMBIA, SC, June 18, 2025 – The Ritedose Corporation, a leading pharmaceutical manufacturer specializing in Blow-Fill-Seal (BFS) technology, today unveiled its new distribution and logistics facility at Performance Park during a ribbon-cutting ceremony. The grand opening event included Ritedose CEO…

Stakeholders open the Ritedose distribution and logistics facility at Performance Park. L–R: Brian Taylor, VP Business Development, Miller Valentine Construction Jeff Ruble, Director, Richland County Economic Development Ashely Teasdel, Deputy Secretary, SC Dept. of Commerce Jody Chastain, CEO, Ritedose Jesica Mackey, Richland County Council District 9 Daniel Rickenmann, Mayor, City of Columbia Ronald Rhames, Fmr. President, Midlands Technical College Greg Little, President, Midlands Technical College

19May2025

Ritedose Pharmaceuticals Receives FDA Approval for Albuterol Sulfate Inhalation Solution, 0.5% (2.5 mg/0.5 mL)*—Addressing Nationwide Shortage of the Essential Drug

COLUMBIA, SC May 20, 2025 —Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), the largest sterile contract development manufacturing organization (CDMO) in the US specializing in aseptic unit-dose medication production using Blow-Fill-Seal (BFS) technology, received US Food and Drug…

FDA approval for albuterol sulfate Solution

1May2025

Ritedose Pharmaceuticals Receives FDA Approval for Generic Formoterol Fumarate Inhalation Treatment for Respiratory Illness

COLUMBIA, SC May 1, 2025 — Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), was granted approval by the US Food and Drug Administration (FDA) to manufacture and market generic formoterol fumarate inhalation solution (20 mcg/2 mL), a treatment…

15April2025

Ritedose Adds Seventh Syntegon Packaging Line to Expand Single Vial Packaging Capabilities, Support Production of new COPD Drug Ohtuvayre

COLUMBIA, S.C. April 16, 2025 – Anticipating a rising need for individually wrapped vial medication manufacturing, The Ritedose Corporation, Inc. (Ritedose) is adding a seventh Syntegon packaging line to its state-of-the-art manufacturing facility that will double the company’s capacity.

7March2025

Ritedose Expands Commitment to Service with 1,000 Hours of Purpose Initiative

COLUMBIA, S.C. – March 6, 2025 – The Ritedose Corporation (Ritedose) announces a groundbreaking new volunteer program: 1,000 Hours of Purpose. “1,000 Hours of Purpose” is a year-long initiative that provides Ritedose employees with the opportunity to dedicate their time,…

21January2025

Ritedose and Newberry College Forge Strategic Partnership to Launch Pharmaceutical Manufacturing Program

COLUMBIA, S.C. Jan. 21, 2025 – In response to the growing demand for skilled professionals in South Carolina’s life sciences sector, The Ritedose Corporation has partnered with Newberry College to launch a new Pharmaceutical Manufacturing program, set to begin in…

Ritedose launch a pharmaceutical program

7October2024

Ritedose Meets Workforce Demand with RISE Program Partnership with InSpring and Benedict College

COLUMBIA, SC – October. 8, 2024 – To meet a need for demanding company roles, The Ritedose Corporation (Ritedose) partnered with inSpring and Benedict College to develop RISE, a workforce initiative for international STEM students at the Historically Black College…

16September2024

Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*

September 17, 2024 — The Ritedose Corporation, Inc. (Ritedose), the largest CDMO in the United States specializing in sterile Blow Fill Seal (BFS) production of unit dose solutions for the ophthalmic and respiratory markets, is proud to partner with Verona…

11August2024

Ritedose Pharmaceuticals Continues Tradition of Giving Back – Increases its Annual Donation to Unprecedented Amount of 1 Million Doses of Respiratory Medications to Dispensary of Hope for Low-income and Chronically lll Patients

COLUMBIA, S.C., August 12, 2024 – Ritedose Pharmaceuticals, a division of The Ritedose Corporation (Ritedose), the leading contract development and manufacturing organization (CDMO) specializing in sterile Blow Fill Seal (BFS) production, announces today that it will donate 1 Million (1M)…

28July2024

Ritedose Named Top 2023 Fundraiser by the American Heart Association

COLUMBIA, S.C. July 29, 2024 – Working together, The Ritedose Corporation (Ritedose) employees raised more than $77,000 during the company’s annual Field Day event this spring in support of the American Heart Association. Additionally, the Association recognized Ritedose as the…

16July2024

Ritedose Interns Volunteer for Food Distribution at State’s Largest Food Bank, Harvest Hope

COLUMBIA, S.C., July 12, 2024 – Eight interns from The Ritedose Corporation (Ritedose) volunteered at the Harvest Hope, South Carolina’s largest food distribution charity this month—packaging boxes of food for needy families on July 10. The humanitarian work was part…

11July2024

Ritedose, the Leading Pharmaceutical Manufacturer (CDMO) Specializing in Sterile Blow-Fill-Seal, Expands its BFS Capacity to Meet the Growing Demand for Ophthalmic and Respiratory Medications

COLUMBIA, S.C. June 20, 2024 – The Ritedose Corporation (Ritedose), the leading contract development and manufacturing organization (CDMO) specializing in sterile Blow Fill Seal (BFS) production, announces a significant expansion of its production capabilities to meet the demand for ophthalmic…

22February2024

Ritedose, South Carolina’s Leading Pharmaceutical Manufacturer, Buys 105 Acres of Land for Major Expansion.

Columbia, S.C. (February 22, 2024) — The Ritedose Corporation (Ritedose) today announced a major expansion of its rapidly-growing pharmaceutical company with the recent purchase of 105 acres from the Midlands Technical College Enterprise Campus in Richland Northeast. (more…)

FEATURED NEWS

30th January 2026

Ritedose Adds Seventh Syntegon Packaging Line to Expand Single Vial Packaging Capabilities, Support Production of new COPD Drug Ohtuvayre

16th September 2024

Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*

11th July 2024

Ritedose, the Leading Pharmaceutical Manufacturer (CDMO) Specializing in Sterile Blow-Fill-Seal, Expands its BFS Capacity to Meet the Growing Demand f…

18th January 2022

The Ritedose Corporation Announces Revolutionary Liquid Med Dispenser SuredoseRx™ to launch in first quarter

4th January 2022

Novo Holdings to acquire Ritedose

RECEIVE THE LATEST NEWS

Get a healthy dose of all things Ritedose. Subscribe now for breaking news alerts, updates, previews, and more.

Ritedose news
and updates.

Media Inquiries

Alex Keown

media@ritedose.com

Introducing Ritedose— the Largest CDMO Specializing in Blow-Fill-Seal Technology in the US

How Ritedose Supports a Stable and Reliable Medication Supply

Ritedose 2025 Year-In-Review

A Season of Gratitude and Purpose: A Thanksgiving Message from Jody Chastain, CEO of Ritedose

Ritedose Now Offers the Largest Nebulized Drug Portfolio in the U.S.: FDA Approves the Company to Manufacture Generic Tobramycin Inhalation Solution

Leading CDMO Enhances cGMP Lab Infrastructure to Strengthen Position

How Blow-Fill-Seal Technology Ensures Sterile Medication Delivery

Ritedose Unveils State-of-the-Art Distribution and Logistics Facility at Ritedose Performance Park

Ritedose Pharmaceuticals Receives FDA Approval for Albuterol Sulfate Inhalation Solution, 0.5% (2.5 mg/0.5 mL)*—Addressing Nationwide Shortage of the Essential Drug

Ritedose Pharmaceuticals Receives FDA Approval for Generic Formoterol Fumarate Inhalation Treatment for Respiratory Illness

Ritedose Adds Seventh Syntegon Packaging Line to Expand Single Vial Packaging Capabilities, Support Production of new COPD Drug Ohtuvayre

Ritedose Expands Commitment to Service with 1,000 Hours of Purpose Initiative

Ritedose and Newberry College Forge Strategic Partnership to Launch Pharmaceutical Manufacturing Program

Ritedose Meets Workforce Demand with RISE Program Partnership with InSpring and Benedict College

Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*

Ritedose Pharmaceuticals Continues Tradition of Giving Back – Increases its Annual Donation to Unprecedented Amount of 1 Million Doses of Respiratory Medications to Dispensary of Hope for Low-income and Chronically lll Patients

Ritedose Named Top 2023 Fundraiser by the American Heart Association

Ritedose Interns Volunteer for Food Distribution at State’s Largest Food Bank, Harvest Hope

Ritedose, the Leading Pharmaceutical Manufacturer (CDMO) Specializing in Sterile Blow-Fill-Seal, Expands its BFS Capacity to Meet the Growing Demand for Ophthalmic and Respiratory Medications

Ritedose, South Carolina’s Leading Pharmaceutical Manufacturer, Buys 105 Acres of Land for Major Expansion.

FEATURED NEWS

Introducing Ritedose— the Largest CDMO Specializing in Blow-Fill-Seal Technology in the US

How Ritedose Supports a Stable and Reliable Medication Supply

Leading CDMO Enhances cGMP Lab Infrastructure to Strengthen Position

How Blow-Fill-Seal Technology Ensures Sterile Medication Delivery

Ritedose Unveils State-of-the-Art Distribution and Logistics Facility at Ritedose Performance Park

Ritedose Adds Seventh Syntegon Packaging Line to Expand Single Vial Packaging Capabilities, Support Production of new COPD Drug Ohtuvayre

Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*

Ritedose, the Leading Pharmaceutical Manufacturer (CDMO) Specializing in Sterile Blow-Fill-Seal, Expands its BFS Capacity to Meet the Growing Demand f…

The Ritedose Corporation Announces Revolutionary Liquid Med Dispenser SuredoseRx™ to launch in first quarter

Novo Holdings to acquire Ritedose

RECEIVE THE LATEST NEWS

TAGS CLOUD

Quick Links

Receive the latest news.

Ritedose news and updates.

Media Inquiries

Alex Keown

FEATURED NEWS

RECEIVE THE LATEST NEWS

TAGS CLOUD

Tags

Quick Links

Receive the latest news.

Ritedose news
and updates.